Open-label, randomized study comparing basal insulin peglispro and insulin glargine, in combination with oral antihyperglycemic medications, in insulin-naive Asian patients with type 2 diabetes.

ABSTRACT:

Introduction

The present phase 3, randomized, open-label study compared the efficacy and safety of basal insulin peglispro with insulin glargine after 26 weeks of treatment when added to oral antihyperglycemic medications in insulin-naïve Asian patients with type 2 diabetes.

Materials and methods

The primary objective was to show non-inferiority of the change in glycated hemoglobin from baseline to 26 weeks.

Results

At 26 weeks, insulin peglispro was non-inferior to glargine, meeting the primary objective. Patients receiving insulin peglispro (n = 192) showed a greater reduction in glycated hemoglobin from baseline compared with glargine (n = 196); -1.6 vs -1.4%, P = 0.005) and in fasting serum glucose (-61.2 vs -54.8 mg/dL, P = 0.02). A significantly higher proportio

SUBMITTER: Hirose T 

PROVIDER: S-EPMC5754544 | biostudies-literature | 2018 Jan

REPOSITORIES: biostudies-literature